US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

26.21

-0.3250-1.23%

Volume:114.07K

Turnover:3.04M

Market Cap:1.45B

PE:-10.41

High:27.44

Open:26.49

Low:26.00

Close:26.53

52wk High:53.65

52wk Low:14.16

Shares:55.25M

Float Shares:37.25M

Volume Ratio:0.89

T/O Rate:0.31%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5172

EPS(LYR):-3.0510

ROE:-37.35%

ROA:-21.79%

PB:3.20

PE(LYR):-8.59

Loading ...

Overview Company News Filings

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75

Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement

Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors

Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares

Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board

Maze Therapeutics Announces Appointments to Its Board of Directors

THOMSON REUTERS

CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge

Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization

Belite Bio Q2 Net Loss Widens on Higher Expenses

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

Humacyte Q2 Net Loss Widens on Inventory, Production Costs

Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln

Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target

Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG

Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate

Benzinga Earnings

Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss

MT Newswires Live

Maze Therapeutics reports Q2 EPS (76c), consensus (70c)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/MAZE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":26.205,"timestamp":1788363243394,"preClose":26.53,"halted":0,"volume":114070,"delay":0,"changeRate":-0.012250282698831619,"floatShares":37250300,"shares":55248700,"eps":-2.517242,"marketStatus":"Trading","change":-0.325,"latestTime":"09-02 11:34:24 EDT","open":26.49,"high":27.44,"low":26,"amount":3042314.77165,"amplitude":0.054278,"askPrice":26.25,"askSize":60,"bidPrice":26.15,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-2.517242,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":26.53,"preHourTrading":{"tag":"盘前","latestPrice":27.28,"preClose":26.53,"latestTime":"09:24 EDT","volume":226,"amount":6165.449952,"timestamp":1788355494387,"change":0.75,"changeRate":0.02827,"amplitude":0.003392},"postHourTrading":{"tag":"盘后","latestPrice":26.53,"preClose":26.53,"latestTime":"19:30 EDT","volume":12171,"amount":322896.19,"timestamp":1788305406649,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.892904,"impliedVol":0.6634,"impliedVolPercentile":0.438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":37250300,"roa":"-21.79%","roe":"-37.35%","lyrEps":-3.051003,"volumeRatio":0.892904,"shares":55248700,"dividePrice":0,"high":27.44,"amplitude":0.054278,"preClose":26.53,"low":26,"week52Low":14.1574,"pbRate":"3.20","psRate":"72.39","week52High":53.65,"institutionHeld":0,"latestPrice":26.205,"committee":-0.690141,"eps":-2.517242,"divideRate":0,"volume":114070,"delay":0,"ttmEps":-2.517242,"open":26.49,"prevYearClose":41.43,"prevWeekClose":27.44,"prevMonthClose":26.57,"prevQuarterClose":29.84,"fiveDayClose":29.58,"twentyDayClose":27.81,"sixtyDayClose":23.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"MAZE","fiscalQuarterEnding":"2026/06","expectedEps":-0.76,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.76},{"market":"US","date":"2026-05-12","symbol":"MAZE","fiscalQuarterEnding":"2026/03","expectedEps":-0.43,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2026-03-25","symbol":"MAZE","fiscalQuarterEnding":"2025/12","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"pre","actualEps":-0.65},{"market":"US","date":"2025-11-06","symbol":"MAZE","fiscalQuarterEnding":"2025/09","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-08-12","symbol":"MAZE","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.77}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1773806400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2026-08-31","current":-10.539312,"percent":0.401515,"low":-19.775245,"twenty":-14.438806,"median":-10.741725,"eighty":9.229128,"high":14.99285,"avg":-4.966708,"sd":11.05252,"marketCap":1524269169},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-08-01","current":12.437825,"twenty":8.267679,"median":9.479345,"eighty":11.289329,"marketCap":646008198},{"date":"2025-08-08","current":11.231989,"twenty":8.274387,"median":9.503122,"eighty":11.660356,"marketCap":583378251},{"date":"2025-08-15","current":-4.846264,"twenty":8.197097,"median":9.495197,"eighty":11.50014,"marketCap":585409301},{"date":"2025-08-22","current":-4.802702,"twenty":7.843394,"median":9.46183,"eighty":11.412442,"marketCap":580147195},{"date":"2025-08-29","current":-5.180239,"twenty":7.675693,"median":9.408012,"eighty":11.34667,"marketCap":625752114},{"date":"2025-09-05","current":-5.459761,"twenty":7.605258,"median":9.384234,"eighty":11.299448,"marketCap":659517295},{"date":"2025-09-12","current":-9.002797,"twenty":7.051844,"median":9.285161,"eighty":11.248853,"marketCap":1087501923},{"date":"2025-09-19","current":-8.523616,"twenty":6.791906,"median":9.217791,"eighty":11.231989,"marketCap":1029618756},{"date":"2025-09-26","current":-9.565472,"twenty":6.372653,"median":9.072896,"eighty":11.223556,"marketCap":1155470793},{"date":"2025-10-03","current":-9.619925,"twenty":-4.846264,"median":8.956237,"eighty":11.080205,"marketCap":1162048426},{"date":"2025-10-10","current":-10.440341,"twenty":-4.897086,"median":8.912645,"eighty":10.903124,"marketCap":1261151423},{"date":"2025-10-17","current":-10.327806,"twenty":-5.035032,"median":8.87091,"eighty":10.852529,"marketCap":1247557649},{"date":"2025-10-24","current":-10.854179,"twenty":-5.43435,"median":8.743704,"eighty":10.801935,"marketCap":1311141431},{"date":"2025-10-31","current":-12.059392,"twenty":-5.764695,"median":8.710535,"eighty":10.776638,"marketCap":1456726366},{"date":"2025-11-07","current":-10.301208,"twenty":-8.440123,"median":8.622163,"eighty":10.742908,"marketCap":1299301692},{"date":"2025-11-14","current":-12.147078,"twenty":-8.530877,"median":8.52824,"eighty":10.604819,"marketCap":1532123096},{"date":"2025-11-21","current":-13.570087,"twenty":-9.148004,"median":8.467465,"eighty":10.501783,"marketCap":1711608623},{"date":"2025-11-28","current":-14.401765,"twenty":-9.516102,"median":8.389744,"eighty":10.458575,"marketCap":1816509011},{"date":"2025-12-05","current":-16.252058,"twenty":-9.864597,"median":8.267679,"eighty":10.366822,"marketCap":2049888314},{"date":"2025-12-12","current":-15.096102,"twenty":-10.151143,"median":8.122944,"eighty":10.312226,"marketCap":1904086399},{"date":"2025-12-19","current":-15.496681,"twenty":-10.373183,"median":7.957431,"eighty":10.278273,"marketCap":1954611815},{"date":"2025-12-26","current":-16.053676,"twenty":-10.591356,"median":7.799992,"eighty":10.266129,"marketCap":2024866203},{"date":"2026-01-02","current":-15.805699,"twenty":-10.832398,"median":7.756189,"eighty":10.248768,"marketCap":1993588564},{"date":"2026-01-09","current":-14.859569,"twenty":-11.164921,"median":7.639287,"eighty":10.225157,"marketCap":1874252343},{"date":"2026-01-16","current":-15.187663,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"marketCap":1915635065},{"date":"2026-01-23","current":-17.625471,"twenty":-12.065201,"median":7.127309,"eighty":10.196366,"marketCap":2223118312},{"date":"2026-01-30","current":-17.167667,"twenty":-12.419472,"median":6.955415,"eighty":10.162555,"marketCap":2165374980},{"date":"2026-02-06","current":-16.767088,"twenty":-13.567798,"median":6.791906,"eighty":10.126096,"marketCap":2114849563},{"date":"2026-02-13","current":-17.945934,"twenty":-14.175152,"median":6.511006,"eighty":10.056348,"marketCap":2263538645},{"date":"2026-02-20","current":-17.182927,"twenty":-14.401765,"median":6.360075,"eighty":9.954897,"marketCap":2167299757},{"date":"2026-02-27","current":-17.48813,"twenty":-14.737488,"median":-4.831743,"eighty":9.883564,"marketCap":2205795312},{"date":"2026-03-06","current":-17.282118,"twenty":-15.149512,"median":-4.864415,"eighty":9.832206,"marketCap":2179810813},{"date":"2026-03-13","current":-19.775245,"twenty":-15.332634,"median":-4.897086,"eighty":9.697287,"marketCap":2494271379},{"date":"2026-03-20","current":-18.857728,"twenty":-15.469975,"median":-4.962429,"eighty":9.697287,"marketCap":2378544116},{"date":"2026-03-27","current":-12.021519,"twenty":-15.550091,"median":-5.100375,"eighty":9.693343,"marketCap":1576261545},{"date":"2026-04-02","current":-11.013091,"twenty":-15.507363,"median":-5.260102,"eighty":9.683007,"marketCap":1444036514},{"date":"2026-04-10","current":-10.569535,"twenty":-15.475316,"median":-5.486987,"eighty":9.652715,"marketCap":1385877385},{"date":"2026-04-17","current":-10.186635,"twenty":-15.415039,"median":-5.764695,"eighty":9.626766,"marketCap":1335671640},{"date":"2026-04-24","current":-10.959561,"twenty":-15.395201,"median":-7.129635,"eighty":9.621519,"marketCap":1437017594},{"date":"2026-05-01","current":-11.209856,"twenty":-15.384518,"median":-8.456458,"eighty":9.590184,"marketCap":1469836362},{"date":"2026-05-08","current":-10.741725,"twenty":-15.342553,"median":-8.527247,"eighty":9.573739,"marketCap":1408454934},{"date":"2026-05-15","current":-11.93693,"twenty":-15.289905,"median":-9.002797,"eighty":9.561199,"marketCap":1462775248},{"date":"2026-05-22","current":-11.629812,"twenty":-15.205975,"median":-9.258724,"eighty":9.520559,"marketCap":1425140470},{"date":"2026-05-29","current":-11.92338,"twenty":-15.178506,"median":-9.458383,"eighty":9.511048,"marketCap":1461114890},{"date":"2026-06-05","current":-11.471737,"twenty":-15.158668,"median":-9.619925,"eighty":9.501537,"marketCap":1405769629},{"date":"2026-06-12","current":-10.880085,"twenty":-15.117466,"median":-9.821399,"eighty":9.495024,"marketCap":1333267337},{"date":"2026-06-18","current":-11.218817,"twenty":-15.001489,"median":-9.973866,"eighty":9.488683,"marketCap":1374776283},{"date":"2026-06-26","current":-12.203399,"twenty":-14.845835,"median":-10.113627,"eighty":9.465333,"marketCap":1495428952},{"date":"2026-07-02","current":-13.463484,"twenty":-14.807685,"median":-10.175262,"eighty":9.440942,"marketCap":1649842230},{"date":"2026-07-10","current":-14.642273,"twenty":-14.807685,"median":-10.243922,"eighty":9.423562,"marketCap":1794293361},{"date":"2026-07-17","current":-12.268888,"twenty":-14.735962,"median":-10.345957,"eighty":9.406427,"marketCap":1503454015},{"date":"2026-07-24","current":-12.506,"twenty":-14.713835,"median":-10.387794,"eighty":9.396916,"marketCap":1532510277},{"date":"2026-07-31","current":-12.478902,"twenty":-14.649742,"median":-10.467027,"eighty":9.384234,"marketCap":1529189561},{"date":"2026-08-07","current":-12.88538,"twenty":-14.642273,"median":-10.571027,"eighty":9.336679,"marketCap":1579000296},{"date":"2026-08-14","current":-11.503614,"twenty":-14.638297,"median":-10.649147,"eighty":9.29705,"marketCap":1536767732},{"date":"2026-08-21","current":-12.029624,"twenty":-14.610658,"median":-10.685878,"eighty":9.273272,"marketCap":1607037430},{"date":"2026-08-28","current":-11.892404,"twenty":-14.448066,"median":-10.740929,"eighty":9.231962,"marketCap":1588706204},{"date":"2026-08-31","current":-11.410054,"twenty":-14.438806,"median":-10.741725,"eighty":9.229128,"marketCap":1524269169}],"updateTime":1788331586423},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664815092","title":"Maze Therapeutics to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815092","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815092?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354981/0/en/maze-therapeutics-to-participate-in-three-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885024","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885024","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885024?lang=en_us&edition=fundamental","pubTime":"2026-09-01 06:33","pubTimestamp":1788215589,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $206,823.75Maze Therapeutics CSBO Atul Dandekar sold 7,500 common shares on Aug. 28, 2026 at USD 27.58.The sale followed the exerci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLJqTrc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778685","title":"Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778685?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:33","pubTimestamp":1787808780,"startTime":"0","endTime":"0","summary":"GENEVA, Aug. 27, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA  , a global leader in scalable precision neurotherapeutics, today announced the publication of its 2026 half-year report and provided a corporate update.Key Highlights-- Expanded U.S. commercial capabilities and reach through the build-out of. the Company's commercial organization, continued development of its. customer pipeline, and a channel partnership with Vibra Healthcare.-- Compelling real-world evidence from a two-year, multi-site program. -- Advanced its European reimbursement strategy with first patient. enrollment in SwissNeuroRehab and launch of the REACT-AVC study in. -- Expanded the clinical application of the platform through support for a. University of Pittsburgh study pairing spinal cord stimulation with. -- Completed organizational simplification, including the disposal of. non-neurology legacy operations, resulting in a focused organization and. -- Received CHF 4.0 million under a CHF 8.0 million ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660324524","title":"Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660324524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660324524?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:46","pubTimestamp":1786999574,"startTime":"0","endTime":"0","summary":"Maze Therapeutics director Paula A. Johnson files initial beneficial ownership statementMaze Therapeutics director Paula A. Johnson filed an initial Form 3 on Aug. 17, 2026.Disclaimer:This news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL78z2DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660328084","title":"Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660328084","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660328084?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:18","pubTimestamp":1786997890,"startTime":"0","endTime":"0","summary":"Maze Therapeutics names Paula Johnson, Sophie Kornowski to board of directorsMaze Therapeutics named Paula Johnson and Sophie Kornowski to its board of directors.Johnson is president of Wellesley Coll","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL87kkJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659712190","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659712190","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659712190?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:58","pubTimestamp":1786741080,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 445,522 common sharesMaze Therapeutics President, R&D and CMO Harold Bernstein sold 16,142 common shares on Aug. 13 at USD 27.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3LPRJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659614160","title":"Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2659614160","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659614160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:49","pubTimestamp":1786654155,"startTime":"0","endTime":"0","summary":"Maze Therapeutics adds Paula Johnson, Sophie Kornowski to boardMaze Therapeutics appointed Paula Johnson and Sophie Kornowski to its board.Johnson is president of Wellesley College, a cardiologist, an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL7LTtBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","LU0345770993.USD","RXL","LU0964807845.USD","FTXH","MAZE","LU0787776722.HKD","IE00BVYPNW00.USD","LU0985320562.USD","NDAQ","BK4585","LU1778281490.HKD","LU1066051811.HKD","IXJ","BK4534","IE00BZ1G4Q59.USD","SGXZ80539844.SGD","LU0320765646.SGD","JNJ","VHT","LU0820561909.HKD","BCDF","IE00BKPKM429.USD","LU0689472784.USD","LU2112291526.USD","LU0345769128.USD","IE00BGHQF631.EUR","LU2471134523.USD","IE000SO60NU8.SGD","IHE","TRUH","XLV","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","IYH","BMED","LU0820562030.AUD","LU2456880835.USD","LU1894683348.USD","LU1244550494.USD","FHLC","LU1043141123.HKD","JDOC","MEDX","LU1221951046.USD","GDOC","LU1732800096.USD","LU2129689431.USD","LU0820561818.USD","LU0689626769.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659351160","title":"Maze Therapeutics Announces Appointments to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2659351160","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659351160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:42","pubTimestamp":1786653745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUABH5JRC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659675701","title":"CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2659675701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659675701?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:22","pubTimestamp":1786652530,"startTime":"0","endTime":"0","summary":"CAMP4 Therapeutics Q2 loss per share misses estimates on non-cash derivative chargeOverviewUS biopharmaceutical developer's Q2 loss per share missed analyst expectationsNet loss widened due to non-cas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELOX","ABEO","BK4020","BK4139","MAZE","CAMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659713511","title":"Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2659713511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659713511?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:00","pubTimestamp":1786600849,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has disclosed a new risk, in the Regulation category. Maze Therapeutics, Inc. faces a material risk that future liti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-threaten-maze-therapeutics-funding-reputation-and-path-to-commercialization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-threaten-maze-therapeutics-funding-reputation-and-path-to-commercialization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659823201","title":"Belite Bio Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659823201","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659823201?lang=en_us&edition=fundamental","pubTime":"2026-08-13 09:55","pubTimestamp":1786586157,"startTime":"0","endTime":"0","summary":"Belite Bio Q2 net loss widens on higher expensesOverviewUS retinal disease drug developer's Q2 net loss widened as R&D and SG&A expenses increasedFDA accepted NDA for tinlarebant with Priority Review ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE","ELOX","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974286","title":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974286?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:40","pubTimestamp":1786534824,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Maze Therapeutics, Inc....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","LABU","BK4007","BK4139","LFSC","LU0029874061.USD","HCSG","MAZE","BK4563","BK4581","FFTY","IMNM","LU0128526141.USD","TVTX","XLV","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971411","title":"Humacyte Q2 Net Loss Widens on Inventory, Production Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971411","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971411?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:11","pubTimestamp":1786533109,"startTime":"0","endTime":"0","summary":"Humacyte Q2 net loss widens on inventory, production costsOverviewU.S. bioengineered tissue maker's Q2 net loss widened, missing analyst expectationsQ2 product revenue for Symvess rose to $0.4 mln fro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PROK","PLRX","BK4139","BK4563","MAZE","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971522","title":"Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971522?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:02","pubTimestamp":1786532528,"startTime":"0","endTime":"0","summary":"Switzerland's Pharvaris Q2 loss narrows, cash rises to 318 mlnOverviewSwitzerland biopharma firm reported Q2 loss per share of 0.70, improving from prior yearCash and equivalents rose to 318 mln, with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","PHVS","MAZE","BK4007","MREO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979623","title":"Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979623","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979623?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:36","pubTimestamp":1786530964,"startTime":"0","endTime":"0","summary":"Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Maze Therapeutics, Inc.. The associated price target remains the same w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-reaffirmed-as-clinical-de-risking-supports-unchanged-110-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-reaffirmed-as-clinical-de-risking-supports-unchanged-110-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976577","title":"Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658976577?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:11","pubTimestamp":1786529460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658263459","title":"Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2658263459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658263459?lang=en_us&edition=fundamental","pubTime":"2026-08-12 13:40","pubTimestamp":1786513200,"startTime":"0","endTime":"0","summary":"significant improvements in patient mobility and self-care, a 60%. increase in delivered therapy per day, and 17% higher community discharge. rates compared to standard of care, while 87% of patients found the. -- the establishment of a U.S. headquarters and Patient Experience Center at. -- the announcement earlier this year of a go-to-market partnership with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4022","R","BK4007","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658794584","title":"Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658794584","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658794584?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:36","pubTimestamp":1786480573,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61128219/maze-therapeutics-q2-eps-0-76-misses-0-73-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943074","title":"Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943074","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943074?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:33","pubTimestamp":1786480425,"startTime":"0","endTime":"0","summary":"Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943150","title":"Maze Therapeutics reports Q2 EPS (76c), consensus (70c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943150?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:16","pubTimestamp":1786479407,"startTime":"0","endTime":"0","summary":"“The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q2-eps-76c-consensus-70c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q2-eps-76c-consensus-70c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":120,"code":"91000000","status":"200"}]}}